CD79B and diffuse large B-cell lymphoma: Our data suggest that dual PI3Kδ and PI3Kα inhibition should be evaluated clinically in ABC DLBCL, with molecular profiling of tumors to determine whether mutations in CD79A or CD79B are enriched in responding patients.